Skip to main content Accessibility help
×
Home
Hostname: page-component-56f9d74cfd-h4v4t Total loading time: 0.692 Render date: 2022-06-26T00:25:32.964Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

14 - Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable

Published online by Cambridge University Press:  19 October 2021

Jonathan M. Meyer
Affiliation:
University of California, San Diego
Stephen M. Stahl
Affiliation:
University of California, Riverside and San Diego
Get access

Summary

Zotepine was approved in Japan in 1982, and is the first antipsychotic modeled on clozapine with relatively high serotonin 5HT2A affinity, lower dopamine D2 affinity, and a corresponding Positron Emission Tomography (PET) imaging profile that demonstrates wide separation between the 5HT2A and D2 occupancy curves in a manner unlike first-generation antipsychotics (FGAs) such as loxapine (see Chapter 11) [12–14]. Zotepine was never approved in the United States (US), Canada, the United Kingdom, Australia, or most European countries, leaving risperidone (US approval December 29, 1993) as the first commercially successful second-generation antipsychotic [15].

Type
Chapter
Information
The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 267 - 295
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

de Leon, J., Wynn, G., and Sandson, N. B. (2010). The pharmacokinetics of paliperidone versus risperidone. Psychosomatics, 51, 8088.
Remington, G., Mamo, D., Labelle, A., et al. (2006). A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry, 163, 396401.
Uchida, H., Takeuchi, H., Graff-Guerrero, A., et al. (2011). Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol, 31, 318325.
Leucht, S., Samara, M., Heres, S., et al. (2014). Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull, 40, 314326.
Schoretsanitis, G., Spina, E., Hiemke, C., et al. (2017). A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol, 10, 965981.
Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice; a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.
Ezewuzie, N. and Taylor, D. (2006). Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia. J Psychopharmacol, 20, 8690.
Ikai, S., Remington, G., Suzuki, T., et al. (2012). A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia. J Clin Psychiatry, 73, 11471152.
Meyer, J. M. (2014). A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr, 19, 432438.
Schoretsanitis, G., Spina, E., Hiemke, C., et al. (2018). A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol, 11, 625639.
Arakawa, R., Ito, H., Takano, A., et al. (2008). Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology, 197, 229235.
Kapur, S., Zipursky, R., Remington, G., et al. (1997). PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry, 154, 15251529.
Barnas, C., Quiner, S., Tauscher, J., et al. (2001). In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl), 157, 236242.
Tauscher, J., Kufferle, B., Asenbaum, S., et al. (2002). Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology, 162, 4249.
Nyberg, S., Farde, L., Eriksson, L., et al. (1993). 5-HT2 and D2 dopamine receptor occupancy in the living human brain: a PET study with risperidone. Psychopharmacology, 110, 265272.
Ereshefsky, L. and Mascarenas, C. A. (2003). Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry, 64, 1823.
Samtani, M. N., Vermeulen, A., and Stuyckens, K. (2009). Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet, 48, 585600.
Gomeni, R., Heidbreder, C., Fudala, P. J., et al. (2013). A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. J Clin Pharmacol, 53, 10101019.
Kapur, S., Zipursky, R. B., and Remington, G. (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry, 156, 286293.
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., et al. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394, 939951.
Gaebel, W., Riesbeck, M., von Wilmsdorff, M., et al. (2010). Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol, 20, 310316.
Boulton, D. W., DeVane, C. L., Liston, H. L., et al. (2002). In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sciences, 71, 163169.
Nakagami, T., Yasui-Furukori, N., Saito, M., et al. (2005). Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther, 78, 4351.
Wang, R., Sun, X., Deng, Y. S., et al. (2018). ABCB1 1199G > A polymorphism impacts transport ability of P-gp-mediated antipsychotics. DNA Cell Biol, 37, 325329.
Linnet, K. and Ejsing, T. B. (2008). A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs. Eur Neuropsychopharmacol, 18, 157169.
Hartter, S., Huwel, S., Lohmann, T., et al. (2003). How does the benzamide antipsychotic amisulpride get into the brain? – An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology, 28, 19161922.
Janssen Pharmaceuticals Inc. (2019). Invega package insert. Titusville, NJ.
Janssen Pharmaceuticals Inc. (2020). Risperdal package insert. Titusville, NJ.
O’Brien, F. E., Dinan, T. G., Griffin, B. T., et al. (2012). Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol, 165, 289312.
Zanger, U. M. and Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 138, 103141.
de Leon, J., Sandson, N. B., and Cozza, K. L. (2008). A preliminary attempt to personalize risperidone dosing using drug–drug interactions and genetics, Part II. Psychosomatics, 48, 347361.
Verbeeck, R. K. (2008). Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol, 64, 11471161.
Meyer, J. M. (2018). Pharmacotherapy of psychosis and mania. In Brunton, L. L., Hilal-Dandan, R. and Knollmann, B. C., eds., Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th edn. Chicago, IL: McGraw-Hill, pp. 279302.
Selmin, F., Blasi, P., and DeLuca, P. P. (2012). Accelerated polymer biodegradation of risperidone poly(D, L-lactide-co-glycolide) microspheres. AAPS PharmSciTech, 13, 14651472.
Fleischhacker, W. W., Eerdekens, M., Karcher, K., et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry, 64, 12501257.
Wilson, W. H. (2004). A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract, 10, 393401.
Kane, J. M., Eerdekens, M., Lindenmayer, J. P., et al. (2003). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry, 160, 11251132.
Meltzer, H. Y., Lindenmayer, J. P., Kwentus, J., et al. (2014). A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophr Res, 154, 1422, https://doi.org/10.1016/j.schres.2014.1002.1015.
Schoretsanitis, G., Spina, E., Hiemke, C., et al. (2018). A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol, 11, 12371253.
Janssen Pharmaceuticals Inc. (2020). Risperdal Consta package insert. Titusville, NJ.
Gefvert, O., Eriksson, B., Persson, P., et al. (2005). Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol, 8, 2736.
Janssen Pharmaceuticals Inc. (2019). Invega Trinza package insert. Titusville, NJ.
Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.
Nasser, A. F., Henderson, D. C., Fava, M., et al. (2016). Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol, 36, 130140.
Ivaturi, V., Gopalakrishnan, M., Gobburu, J. V. S., et al. (2017). Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. Br J Clin Pharmacol, 83, 14761498.
Southard, G. L., Dunn, R. L., and Garrett, S. (1998). The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease. Expert Opin Investig Drugs, 7, 14831491.
Meyer, J. M. (2018). Risperidone extended-release injectable suspension. Curr Psychiatr, 17, 2333.
Laffont, C. M., Gomeni, R., Zheng, B., et al. (2014). Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet, 53, 533543.
Laffont, C. M., Gomeni, R., Zheng, B., et al. (2015). Population pharmacokinetic modeling and simulation to guide dose selection for RBP-7000, a new sustained-release formulation of risperidone. J Clin Pharmacol, 55, 93103.
Indivior Inc. (2019). Perseris package insert. North Chesterfield, VA 23235.
Janssen Pharmaceuticals Inc. (2019). Invega Sustenna package insert. Titusville, NJ.
Pandina, G. J., Lindenmayer, J. P., Lull, J., et al. (2010). A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol, 30, 235244, https://doi.org/210.1097/JCP.1090b1013e3181dd3103.
Chouinard, G., Jones, B., Remington, G., et al. (1993). A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol, 13, 2540.
Marder, S. R. and Meibach, R. C. (1994). Risperidone in the treatment of schizophrenia. Am J Psychiatry, 151, 825835.
Peuskens, J. (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry, 166, 712726; discussion 727733.
Merlo, M. C., Hofer, H., Gekle, W., et al. (2002). Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry, 63, 885891.
Li, C., Xia, J., and Wang, J. (2009). Risperidone dose for schizophrenia. Cochrane Database Syst Rev, CD007474.
Kapur, S., Zipursky, R., Jones, C., et al. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry, 157, 514520.
Remington, G., Kapur, S., and Zipursky, R. (1998). The relationship between risperidone plasma levels and dopamine D2 occupancy: a positron emission tomographic study. J Clin Psychopharmacol, 18, 8283.
Karlsson, P., Hargarter, L., Dencker, E., et al. (2007). Pharmacokinetics and dopamine D2 and serotonin 5-HT2a receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies (PAL-115). Pharmacopsychiatry, 40, A106.
Leucht, S., Crippa, A., Siafis, S., et al. (2020). Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry, 177, 342353.
Samtani, M. N., Gopal, S., Gassmann-Mayer, C., et al. (2011). Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs, 25, 829845.

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×